Gilead CEO Daniel O’Day saw another rise in his pay in 2024, reflecting the steadily upward trajectory of the company since ...

Gilead Sciences Inc. CEO Daniel O'Day's compensation rose 4.8% last year to $23.7 million — roughly $97 for every buck made ...

Roche executive Daniel O’Day is to take the helm at Gilead after John Milligan steps down as CEO at the end of this year, the company has announced. Currently CEO of Roche Pharmaceuticals since ...

CEO Daniel O'Day highlighted strong Q4 results with ... especially in underserved populations. Gilead Sciences delivered strong 2024 results, driven by robust HIV and oncology performance.

Gilead Sciences Inc. closed 10.06% short of its 52-week high of $119.96, which the company achieved on March 10th.

Gilead Sciences (GILD) stock fell after The Wall Street Journal reported that the Health and Human Services Department is looking at ...

Gilead Sciences has revealed its pricing plans for coronavirus drug remdesivir – and the rationale behind its decision. In an open letter, the company’s chief executive Daniel O’Day reveals ...

Bay Area drug giant Gilead is plotting the trial of a groundbreaking, once-a-year HIV prevention drug lenacapavir.